Randall Bateman, M.D.

Charles F. and Joanne Knight Distinguished Professor of Neurology,

Washington University School of Medicine

Dr. Randall Bateman attended Washington University where he received a B.S. degree in Biology and also in Electrical Engineering. He then received a M.D. at Case Western Reserve University School of Medicine.

Dr. Bateman is the Director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in the DIAN. Dr. Bateman also serves as the Associate Director of the Dominantly Inherited Alzheimer Network (DIAN), the DIAN Clinical Core leader, and the Washington University DIAN Performance Site PI. Dr. Bateman is the recipient of multiple grants and awards from the NIH and outside agencies.

Dr. Bateman’s laboratory investigates the causes and future diagnostic tests and treatments of Alzheimer's disease utilizing a wide variety of assays and techniques from quantitative measurement of stable-isotope labeled proteins to clinical translational studies for Alzheimer's disease. Recent awards include Scientific American 50, top 50 scientific advancements of 2006, Beeson Award (2007), the Glenn Award for Research (2011), the Alzforum Open Innovation Award (2011), the Metlife Promising Investigator Award (2012), and the Chancellor’s Entrepreneurship and Innovation Award (2013).

Funded Research

Project Description Researchers Funding
APOE Proteoforms in Human CNS and Validation of APOE Pharmacodynamic Translational Markers

APOE is the single greatest risk factor for Alzheimer’s disease and causes up to half of all AD. The reasons for this genetic risk factor are uncertain, but there are several key ways APOE could cause AD. This includes different kinds, function, stability or amounts of APOE causing increased risk of amyloidosis and neurodegeneration. However, until recently, it has been challenging to accurately compare the amounts and kinds of different forms of APOE (there are three common forms called APOE2, APOE3 and APOE4).

2017
$250,000
Orbitrap Fusion Tribrid Mass Spectrometer
The proposed grant will assist in the purchase of an Orbitrap Fusion Tribrid Mass Spectrometer system to enable the development of a method to assess tau production and clearance rates in humans, animal models, and in vitro experiments. This cutting edge mass spectrometer system will provide more precise measurements with the ultra-low abundance of biomolecules of interest than current instruments can quantify. This will allow for the first time the measuring of tau kinetics enabling evaluation of tau directed therapeutics in animal models, tau kinetics in humans (e.g.
2014
$200,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.
Norelle C. Wildburger, Thomas J. Esparza, Richard D. LeDuc, Ryan T. Fellers, Paul M. Thomas, Nigel J. Cairns, Neil L. Kelleher, Randall J. Bateman, David L. Brody, Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain, Scientific Reports, 7, 25 Aug 2017
Vitaliy Ovod, Kara N. Ramsey, Kwasi G. Mawuenyega, Jim G. Bollinger, Terry Hicks, Theresa Schneider, Melissa Sullivan, Katrina Paumier, David M. Holtzman, John C. Morris, Tammie Benzinger, Anne M. Fagan, Bruce W. Patterson, Randall J. Bateman, Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis, Alzheimers & Dementia, 13(8), Aug 2017, 841-849